New agreement to enhance production of Copper-64 for medical use
- Clarity partners with Theragenics for Copper-64 production
- Agreement aims to improve availability for medical use
- Copper-64 is used in advanced cancer diagnostic procedures
Clarity has entered into a significant manufacturing supply agreement with Theragenics to produce Copper-64, a key isotope used in various medical applications. This agreement is expected to enhance the availability of Copper-64, which plays a crucial role in advanced diagnostic imaging and therapeutic procedures for cancer. The partnership marks a strategic move to bolster the production capabilities of this essential radiopharmaceutical.
As part of the agreement, Clarity will supply Copper-64 to Theragenics, facilitating its distribution for medical use. The initiative is designed to meet the increasing demand for the isotope in diagnostic imaging and treatment, addressing a notable gap in the current supply chain for radiopharmaceuticals. This collaboration highlights the ongoing efforts to improve patient care through enhanced access to advanced medical technologies.
Copper-64 is particularly valued for its applications in positron emission tomography (PET) imaging, which enables healthcare providers to detect and monitor cancerous lesions. The agreement between Clarity and Theragenics embodies a commitment to advancing the production and use of radiopharmaceuticals, ensuring that medical professionals have the necessary tools for effective patient management.
